Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F22%3A43922689" target="_blank" >RIV/00064173:_____/22:43922689 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/22:43922689

Výsledek na webu

<a href="https://doi.org/10.1007/s13555-021-00672-z" target="_blank" >https://doi.org/10.1007/s13555-021-00672-z</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13555-021-00672-z" target="_blank" >10.1007/s13555-021-00672-z</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Popis výsledku v původním jazyce

Psoriasis vulgaris is a chronic immune-mediated inflammatory disease of the skin. Biologic therapy has been available for more than ten years and has become one of the standard treatments for patients with moderate to severe psoriasis. Firstly, drugs against tumour necrosis factor alpha (TNF-α) were used and only later drugs against different interleukins (IL) like 17 or 23 became available. Side effects of biologic therapy include paradoxical adverse events (PAE) like palmoplantar pustular reaction, especially with anti-TNF-α drugs. We present a case of a 49-year old female diabetic patient with psoriasis and psoriatic arthritis treated with an adalimumab biosimilar who developed a severe PAE of the palmoplantar pustular type. Adalimumab was stopped and the patient was switched to ixekizumab which was successful. When a paradoxical reaction develops during biologic therapy, especially when it is severe like in our patient, switching to another class of biologics is advised.

Název v anglickém jazyce

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Popis výsledku anglicky

Psoriasis vulgaris is a chronic immune-mediated inflammatory disease of the skin. Biologic therapy has been available for more than ten years and has become one of the standard treatments for patients with moderate to severe psoriasis. Firstly, drugs against tumour necrosis factor alpha (TNF-α) were used and only later drugs against different interleukins (IL) like 17 or 23 became available. Side effects of biologic therapy include paradoxical adverse events (PAE) like palmoplantar pustular reaction, especially with anti-TNF-α drugs. We present a case of a 49-year old female diabetic patient with psoriasis and psoriatic arthritis treated with an adalimumab biosimilar who developed a severe PAE of the palmoplantar pustular type. Adalimumab was stopped and the patient was switched to ixekizumab which was successful. When a paradoxical reaction develops during biologic therapy, especially when it is severe like in our patient, switching to another class of biologics is advised.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatology and Therapy

ISSN

2193-8210

e-ISSN

2190-9172

Svazek periodika

12

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

5

Strana od-do

605-609

Kód UT WoS článku

000745815600001

EID výsledku v databázi Scopus

2-s2.0-85123471275